- Sector
- Pharmaceuticals, Manufacturing
- Country
- Egypt
An Egyptian pharmaceutical manufacturer, established in 2010 and headquartered in Nasr City, Cairo. It began marketing in 2015 with a range of hepatitis C treatments, and says that working with the Egyptian Ministry of Health and the Egyptian Liver Research Institute it treated more than 60,000 patients with them.
It now makes its own portfolio across several therapeutic areas, from an empagliflozin treatment for type 2 diabetes to an apixaban anticoagulant, in a 7,500 m² plant built to cGMP standards, and offers toll manufacturing and private label to other companies. In 2020 the EBRD began consultancy studies to qualify the plant for European GMP accreditation, with exports to the EU, the Middle East and Africa as the aim. The company puts its own figures at more than 25 marketed products and 590 employees.
Source: the company’s website